David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.
David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University (OSU) College of Medicine; and director of the Division of Gynecologic Oncology; director of Clinical Research in Gynecologic Oncology; and co-director of the Gynecologic Oncology Phase I Program at The OSU Comprehensive Cancer Center–James, discusses the utility of mirvetuximab soravtansine (IMGN853) in ovarian cancer.
Historically, mirvetuximab has been shown to be continuously beneficial in multiple areas of treatment, most notably in platinum-resistant ovarian cancer, says O’Malley. However, data have also been previously reported on mirvetuximab combined with carboplatin and bevacizumab (Avastin) and exciting data have been reported with this triplet combination, adds O’Malley.
Now, mirvetuximab may offer an opportunity to replace paclitaxel in the ovarian cancer space. It is well-known that paclitaxel causes several adverse events, such as alopecia and neuropathy, and it is possible that mirvetuximab could replace it as a better option with less toxicity and potentially improved efficacy, concludes O’Malley.